Specialized cancer care will be offered to cancer patients making it accessible and affordable. We have adopted a patient-centric approach.
The company is relieving all its staff who were directly engaged by our US subsidiary in its plant in connection with the manufacturing process in a phased manner
WCK 5222 is a Super-drug which is entirely a new class of antibiotic known as "?-lactam ENHANCER".
Parkinson’s is not limited to old people, even youngsters can suffer from this disease
The facility will produce 150 million vaccine doses per year
The USFDA has granted a qualified infectious disease product (QIDP) designation to WCK 6777, which signifies its ability to meet unmet medical needs and facilitates a faster approval process
The facility is spread across 215000 sq. feet and provides super-speciality care
Wockhardt has entered into an agreement with Russian Direct Investment Fund and Enso Healthcare to manufacture and supply Sputnik V and Sputnik Light vaccines against Covid-19
The Board of Directors of Wockhardt have approved the unaudited consolidated financial results for the period ended September 30, 2021.
The company to receive upfront and milestone payments, in addition to royalties
Subscribe To Our Newsletter & Stay Updated
